Physician profile
Albert Smith
NPI 1366544280
$9,143.79
in general payments reported to CMS, 2019-2025
53 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $616 · 2021: $1,495 · 2022: $1,700 · 2023: $1,600 · 2024: $1,507 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,547 · Education: $30.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,547.00 |
| Education | $30.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,543.10 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $1,079.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $685.24 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $673.97 | 2019-2025 | |
| Abbvie INC. | $626.74 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $477.32 | 2021-2025 | |
| Harmony Biosciences LLC | $447.20 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.39 | 2019-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $368.85 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $292.50 | 2019-2025 | Spravato |
| Pfizer INC. | $254.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $250.34 | 2023-2025 | Breztri, Farxiga, Fasenra |
| Astellas Pharma US INC | $231.30 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $199.14 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.99 | 2023-2025 | Caplyta |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.